Whole Exome Sequencing Identifies Variable Expressivity of CLN6 Variants in Progressive Myoclonic Epilepsy Affected Families

Progressive myoclonic epilepsies (PMEs) are a group of neurodegenerative disorders, predominantly affecting teenagers and, characterized by generalized worsening myoclonus epilepsies, ataxia, cognitive deficits, and dementia. To date, several genes, having implications in diverse phenotypic expressions associated with PMEs, have been identified. Genetic diagnosis is available for most of the adolescence-onset myoclonic epilepsies. This study aimed to elucidate the genetic basis of PMEs in three multiplex Pakistani families exhibiting clinically variable phenotypes. Causative variant(s) in the studied families, and mode of segregation were identified by Whole Exome Sequencing (WES) of the probands, followed by Sanger sequencing for final validation. We identified homozygous recessive CLN6missense variantc.768C>G(p.Asp256Glu) in Family 1, andc.889C>A(p.Pro297Thr) variant in Family 2. While in Family 3, we found a homozygous variant (c.316dup) that caused a frameshift mutation, leading to a premature stop codon in the CLN6 protein, resulting in a truncated protein (p.Arg106ProfsTer26).Though CLN6is previously identified to underlie late infantile and adolescent onset neuronal ceroid lipofuscinosis, this study supports, and expands the phenotypic spectrum of CLN6mutations and, the significance of therapeutically potentialCLN6 variants (c.768C>G, c.889C>A and c.316dup) in diagnosing PMEs. Diverse pathological effects of variant c.768C>G are observed Family 1, with same genotypes, suggesting clinical heterogeneity and/or variable expressivity that might be the implication of pleiotropic effects of the gene in this case.